Skip to main
AMPH
AMPH logo

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. has demonstrated strong sales momentum with Baqsimi, reflecting a nearly 20% quarter-over-quarter increase in prescriptions during the third quarter of 2025, which positions the company for favorable growth in 2025 and 2026. The company anticipates a return to double-digit growth by 2026, supported by expected high-single digit unit growth in 2025 and strong performance from Primatene Mist during the upcoming fall and winter seasons. Additionally, favorable market conditions indicate that Amphastar's top-line growth could align more closely with industry peers, thereby enhancing its overall financial outlook.

Bears say

Amphastar Pharmaceuticals Inc. faces a negative outlook primarily due to significant revisions in sales expectations for key products, particularly iron sucrose and glucagon, which are projected to experience substantial decline amid increasing competition. Sales estimates for iron sucrose have been drastically reduced from an anticipated $60 million annually to around $20 million, while glucagon revenues are expected to fall below $70 million starting in 2026, impacted by the entry of multiple competitors into the market. Additionally, the firm's forecast for top-line growth has been downgraded from double-digit growth to a more modest range of high-single to low-double digits, reflecting ongoing pressures from their product pipeline and market dynamics.

Amphastar Pharma (AMPH) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Buy based on their latest research and market trends.

According to 5 analysts, Amphastar Pharma (AMPH) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.